Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsing Remitting Multiple Sclerosis: full-pipeline trial registry
5 of 27 indexed Relapsing Remitting Multiple Sclerosis trials are currently recruiting.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 5 currently recruiting · #598 of 28,707 conditions by registered trial count
Relapsing Remitting Multiple Sclerosis: 27 US clinical trials tracked, 5 recruiting.
Relapsing Remitting Multiple Sclerosis is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 3 of these trials.
Enrollment posture brief
Registry condition relapsing-remitting-multiple-sclerosis
OPEN 5 | RECR 19% | LATE 6 | EARLY 7 | RANK #598 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Asthma (19% recruiting · 378 trials)
Relapsing Remitting Multiple Sclerosis lists 5 open slots (19% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsing Remitting Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsing Remitting Multiple Sclerosis is recruiting below its size-band peers.
5 of 27 indexed trials (18.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Relapsing Remitting Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 3 of 27 trials (11.1%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Relapsing Remitting Multiple Sclerosis enrolment sits around 80 participants.
Median target enrolment is 80 among the 26 trials that report a genuine target (sentinel values excluded). 14 of those (53.8%) plan for fewer than 100 participants.
-
Relapsing Remitting Multiple Sclerosis splits between interventional and observational designs.
18 interventional and 9 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
Hoffmann-La Roche
NCT05949580
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04047628
Functional Outcomes From Diets in Multiple Sclerosis
University of Alabama at Birmingham
NCT05327322
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
University of Louisville
NCT00919217
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
NCT06796504
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Hoffmann-La Roche
NCT05123703
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
NCT05090371
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
Terry L. Wahls
NCT04009005
Serum Neurofilament Light in Multiple Sclerosis
Dent Neuroscience Research Center
NCT06282081
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
University of Southern California
NCT05171972
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
Kessler Foundation
NCT05755061
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Biogen
NCT00420212
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Novartis Pharmaceuticals
NCT01623596
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
Biogen
NCT03093324
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals
NCT00879658
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Contineum Therapeutics
NCT06083753
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
University of California, Los Angeles
NCT00451204
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
Novartis
NCT06395909
Development of a Motivational Intervention to Improve Treatment Adherence in MS
University of Missouri, Kansas City
NCT01925690
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Biogen
NCT01244139
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
University of Virginia
NCT03718247
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
Providence Health & Services
NCT03157830
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
EMD Serono Research & Development Institute
NCT03284970
Melatonin in Patients With Multiple Sclerosis (MS).
Providence Health & Services
NCT03498131
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
OhioHealth
NCT02258217
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
University of Southern California
NCT01456416
Vitamin D Pilot Study in Patients With Multiple Sclerosis
University of Wisconsin, Madison
NCT01257958
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsing Remitting Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsing Remitting Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsing Remitting Multiple Sclerosis page
27 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Relapsing Remitting Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Relapsing Remitting Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsing Remitting Multiple Sclerosis condition card totals 27 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.